Haloperidol Decanoat Neuraxpharm

Haloperidol Decanoate Neuraxpharm is a prescription‑only intramuscular injection containing the active ingredient haloperidol decanoate, a long‑acting butyrophenone antipsychotic. Marketed in the European Union, the product is supplied as a sterile oil‑based depot formulation intended for deep muscle administration. It belongs to the typical antipsychotic class and works by antagonising dopamine D2 receptors, providing sustained plasma concentrations for the management of certain psychiatric conditions in adult patients.

Haloperidol Decanoate Neuraxpharm is indicated for several psychiatric conditions where a long‑acting injectable antipsychotic is preferred to improve adherence and provide stable drug exposure.

- Schizophrenia, including maintenance therapy after acute stabilization, to reduce relapse risk. - Acute psychotic episodes when rapid symptom control is needed and oral administration is impractical. - Long‑term relapse prevention in patients with a documented history of recurrent psychotic episodes. - Tourette syndrome, as an adjunct for severe motor and vocal tics unresponsive to first‑line agents. - Clinician‑guided off‑label use for other chronic psychotic disorders where depot therapy may be beneficial.

The safety profile of haloperidol decanoate reflects its pharmacologic activity as a dopamine antagonist, with both expected and less frequent adverse events that clinicians monitor during therapy.

Common: - Sedation or drowsiness, especially after injection. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Weight gain or changes in appetite. - Blurred vision or visual disturbances. - Nausea or vomiting.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary movements of the face or limbs. - Severe hypotension or cardiac arrhythmias. - Hyperprolactinemia leading to menstrual disturbances or galactorrhea. - Agranulocytosis or severe leukopenia (very uncommon).

When prescribing haloperidol decanoate, healthcare professionals should consider several precautionary measures to minimize risks and ensure appropriate patient selection.

- Assess cardiovascular status, especially for patients with a history of arrhythmias or hypotension. - Evaluate for prior extrapyramidal reactions or tardive dyskinesia before initiating therapy. - Use caution in patients with hepatic or renal impairment, adjusting monitoring as needed. - Discuss potential pregnancy and lactation risks, as safety data are limited. - Monitor prolactin levels regularly to detect hyperprolactinemia. - Review concomitant medications that may prolong QT interval. - Ensure patients understand the importance of adherence to scheduled injections.

Haloperidol decanoate may interact with other drugs that influence dopamine pathways, cardiac conduction, or metabolic clearance, requiring careful review of a patient’s medication list.

Avoid: - Other antipsychotics or dopamine antagonists, which can increase the risk of extrapyramidal symptoms and sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma concentrations.

Use with caution: - CYP3A4 inducers such as carbamazepine or rifampin, which could reduce drug exposure. - Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Central nervous system depressants, including benzodiazepines or opioids, which may enhance sedation. - Anticholinergic agents, which can mask early signs of extrapyramidal side effects.